Condition: Metastatic Breast Cancer · Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer who have previously failed endocrine therapy.
This description comes directly from the study's public registry record.
Yina Diao · 86-028-67252634 · diaoyina@kelun.com
Always discuss trial participation with your own doctor first.
| The Fifth Medical Center of the Chinese PLA General Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07071337